Dr Sheeba Irshad, clinical deputy head of the Breast Cancer Now Research Unit at Kings College London, answers some common questions about the current COVID-19 vaccines and breast cancer.
Today we’ve launched a campaign featuring three women who have had a diagnosis of breast cancer or are living with the disease.
Women invited for screening as part of the NHS Breast Screening Programme in England will receive a new information leaflet.
It’s Breast Cancer Awareness Month in October when the media focus gives us a great chance to remind people about the importance of being breast aware.
These are the rules which apply to your participation in our “Ladies Day” Facebook competition.
1. The promoter of the prize draw is Breast Cancer Care 5-13 Great Suffolk Street London SE1 0NS in partnership with Arena Racing Corporation Ltd.
2. The prize draw is open to UK residents aged 18 or over excluding Breast Cancer Care and Arena Racing Corporation Ltd employees their immediate family or any person or company associated with the draw.
A breast cancer diagnosis is difficult for anyone to take in. However it’s easy to forget about the impact it can have on close family and friends. This may include a partner mother sister child or an employer or work colleague to name but a few.
Being diagnosed with secondary breast cancer can affect the people around you in different ways whether it’s a partner family or friends.
Earlier in the year we made a video about talking to people about secondary breast cancer. The video features Tara Beaumont a clinical nurse specialist and Marie who was diagnosed with secondary breast cancer five years ago.
The first in-depth study of people with secondary breast cancer has found that current care is inadequate.
The study which was published in BMJ Supportive & Palliative Care followed the experiences of 10 women with secondary breast cancer aged between 40 and 78. The study was part of a previously published survey of 235 women by Dr Elizabeth Reed for Breast Cancer Care.
Draft guidance from the National Institute for Health and Care Excellence (NICE) has recommended that a drug called pertuzumab (Perjeta) should not be used by the NHS to treat a type of secondary breast cancer.
In July NICE rejected another drug for treating secondary breast cancer called everolimus (Afinitor).
I look after the Moving Forward gallery on our website as one part of my work here in the Marketing team.
The gallery's open to anyone moving on from hospital-based treatment for breast cancer to share their experiences and a photo.